Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

Author： Hamnvik Ole-Petter R.   Choueiri Toni K.   Turchin Alexander   McKay Rana R.   Goyal Lipika   Davis Michael   Kaymakcalan Marina D.   Williams Jonathan S.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|121|2|311-319

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.2, 2015-01, pp. : 311-319

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors

By  

Current Radiopharmaceuticals, Vol. 6, Iss. 1, 2013-03 ,pp. : 48-55

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment and Control of BP and Lipids in Patients with Hypertension and Additional Risk Factors

By Welch Verna  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 5, 2007-01 ,pp. : 381-389

Adis International

Access to resources Recommend Favorite

Anti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2680-2701

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Inhibitors of Stat3 Signaling Pathway

By  

Current Cancer Drug Targets, Vol. 7, Iss. 1, 2007-01 ,pp. : 91-107

Bentham Science Publishers

Access to resources Recommend Favorite

VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

By  

Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-01 ,pp. : 624-653

Bentham Science Publishers

Access to resources Recommend Favorite